Thompson H J, McGinley J N, Wolfe P, Singh M, Steele V E, Kelloff G J
Centers for Cancer Causation and Prevention, AMC Cancer Research Center, Lakewood, CO 80214, USA.
Carcinogenesis. 1998 Dec;19(12):2181-5. doi: 10.1093/carcin/19.12.2181.
An experimental model for mammary carcinogenesis has been described in which intraductal proliferations, ductal carcinomas in situ and adenocarcinomas can be readily detected and the frequency of their occurrence quantified. The objective of the experiment reported in this study was to determine the latency period between carcinogen administration and the occurrence of each of these types of lesion. A total of 150 female Sprague-Dawley rats were injected i.p. with 50 mg 1-methyl-1-nitrosourea (MNU)/kg body wt at 21 days of age. Groups of 30 rats each were killed at 7, 14, 21, 28 and 35 days post-carcinogen. Mammary intraductal proliferations were the first detected lesions and were observed in 20% of the animals at 14 days following carcinogen administration. At 21 days post-carcinogen ductal carcinomas in situ and adenocarcinomas were observed. The number of each type of lesion increased with time post-carcinogen, but the temporal pattern of occurrence was different among lesion types. The pattern of lesion occurrence was consistent with intraductal proliferations being a precursor lesion for ductal carcinomas in situ and adenocarcinomas. Furthermore, the data imply that ductal carcinomas in situ represent one pathway of morphological progression by which intraductal proliferations evolve into invasive carcinomas, but that this lesion type, as currently defined histologically, may not be an obligatory intermediate in morphologic progression. These findings are consistent with emerging evidence of multiple but distinct pathogenetic pathways leading to mammary carcinomas that display different morphological patterns and biological activities.
已描述了一种用于乳腺癌发生的实验模型,在该模型中可轻易检测到导管内增生、原位导管癌和腺癌,并对其发生频率进行量化。本研究报告的实验目的是确定给予致癌物与每种类型病变发生之间的潜伏期。总共150只雌性Sprague-Dawley大鼠在21日龄时腹腔注射50 mg 1-甲基-1-亚硝基脲(MNU)/kg体重。在给予致癌物后的第7、14、21、28和35天,每组30只大鼠被处死。乳腺导管内增生是最早检测到的病变,在给予致癌物后14天,20%的动物出现了这种病变。在给予致癌物后21天,观察到原位导管癌和腺癌。每种类型病变的数量随给予致癌物后的时间增加,但不同类型病变的发生时间模式不同。病变发生模式与导管内增生是原位导管癌和腺癌的前驱病变一致。此外,数据表明原位导管癌代表了导管内增生演变为浸润性癌的一种形态学进展途径,但就目前组织学定义而言,这种病变类型可能不是形态学进展中的必经中间阶段。这些发现与导致乳腺癌的多种但不同的致病途径的新证据一致,这些途径表现出不同的形态模式和生物学活性。